Enroll in Research > Research Search & Enroll Tool > Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer
Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT0823654

Quality of Life:
High Risk But No Cancer, Breast Cancer Survivor

Study Contact Information:

For additional information, please contact:

Shari Goldfarb, MD at: 646-888-5080

Kimberly Van Zee, MD at: 646-888-5362


Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

About the Study

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

What the Study Entails

The study will enroll two groups of participants:

  • Premenopausal women with early-stage breast cancer
  • High-risk women with BRCA mutations (and no evidence of breast or ovarian cancer)

Patients in both of the study groups will undergo blood draws, complete questionnaires, and provide monthly menstrual calendars to the study team at intervals for approximately two years.   

For the high-risk women with BRCA mutations (and no evidence of breast or ovarian cancer), they have an option to participate in annual follow-up for an additional three years.

Study Locations

New Jersey

Memorial Sloan Kettering Basking Ridge      
Basking Ridge, New Jersey
Contact: Shari Goldfarb, MD    646-888-5080     

Memorial Sloan Kettering Monmouth          
Middletown, New Jersey
Contact: Shari Goldfarb, MD    646-888-5080     

Memorial Sloan Kettering Bergen     
Montvale, New Jersey
Contact: Shari Goldfarb, MD    646-888-5080     

New York

Memorial Sloan Kettering Commack
Commack, New York
Contact: Shari Goldfarb, MD    646-888-5080     

Memorial Sloan Kettering Westchester        
Harrison, New York
Contact: Shari Goldfarb, MD    646-888-5080     

Memorial Sloan Kettering Cancer Center     
New York, New York
Contact: Shari Goldfarb, MD    646-888-5080     
Contact: Kimberly Van Zee, MD    646-888-5362              

New York Presbyterian Hospital-Weill Medical College of Cornell University         
New York, New York

Memorial Sloan Kettering Nassau     
Uniondale, New York
Contact: Shari Goldfarb, MD    646-888-5080   

This Study is Open To:

For Premenopausal Women with Early-Stage Breast Cancer

  • Premenopausal women age 18-44 with Stage 0-III breast cancer, before the start of planned chemotherapy and/or hormonal therapy
  • Have regular menstrual cycles

For High-Risk Premenopausal Women with BRCA mutation

  • Premenopausal Women ages 25-45 with known BRCA mutation
  • No history of breast or ovarian cancer
  • Have regular menstrual cycles
This Study is Not Open To:

Patients will be excluded if they have:  

General

  • Prior known infertility
  • Family history of a first-degree relative with non-surgical menopause < age 40
  • Current pregnancy

Exclusion Criteria: For Premenopausal Women with Early-Stage Breast Cancer

  • Had prior therapy for breast cancer or any other cancer, such as chemotherapy, hormonal therapy or immunotherapy.
  • Had an ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to pelvic region.
  • Plans for risk-reducing bilateral oophorectomy within one year of completion of chemotherapy.

Exclusion Criteria: For High-Risk Premenopausal Women with BRCA mutation

  • Had prior chemotherapy or immunotherapy for breast cancer or any other cancer
  • Had an ovarian resection, unilateral or bilateral oophorectomy, hysterectomy, radiation to pelvic region, or ovarian disease (e.g. polycystic ovarian syndrome).
  • Plans for risk-reducing bilateral oophorectomy within one year